secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001641172-25-008748
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma reports no brain toxicity in FDA-required Ketamir-2 study
---------------------------------------------------------------------

- Ketamir-2 showed no mortality, adverse signs, or brain lesions in rats at high doses.
- Positive control MK-801 caused vacuolation and neuronal necrosis (Olney lesions).
- Results to be submitted to FDA as part of ongoing regulatory communications.
- Study supports Ketamir-2's safety profile versus ketamine-linked neurotoxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225008748/0001641172-25-008748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225008748/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-008748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer